Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Calves

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouseP O Livingston, G Ritter, M J Calves
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1987
Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cellsP O Livingston, M J Calves, E J Natoli
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 10, 2017
[Outcomes of GreenLight XPS-180W laser photovaporization for BPH larger than 80mL]M Thoulouzan, M-A Perrouin-Verbe, J Calves, et al.
Immunobiology|December 1, 1990
Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouseG Ritter, E Boosfeld, M J Calves, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1987
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patientsP O Livingston, E J Natoli, M J Calves, et al.
Vaccine|September 1, 1993
GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3P O Livingston, M J Calves, F Helling, et al.
Cancer Research|December 15, 1989
Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 gangliosideP O Livingston, G Ritter, P Srivastava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1994
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 gangliosideP O Livingston, G Y Wong, S Adluri, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 5, 2017
[Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study]P Léon, G Cancel-Tassin, N Koutlidis, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Léon, N Kloutidis, J Calves, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouseP O Livingston, G Ritter, M J Calves
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1987
Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cellsP O Livingston, M J Calves, E J Natoli
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 10, 2017
[Outcomes of GreenLight XPS-180W laser photovaporization for BPH larger than 80mL]M Thoulouzan, M-A Perrouin-Verbe, J Calves, et al.
Immunobiology|December 1, 1990
Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouseG Ritter, E Boosfeld, M J Calves, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1987
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patientsP O Livingston, E J Natoli, M J Calves, et al.
Vaccine|September 1, 1993
GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3P O Livingston, M J Calves, F Helling, et al.
Cancer Research|December 15, 1989
Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 gangliosideP O Livingston, G Ritter, P Srivastava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1994
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 gangliosideP O Livingston, G Y Wong, S Adluri, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 5, 2017
[Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study]P Léon, G Cancel-Tassin, N Koutlidis, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Léon, N Kloutidis, J Calves, et al.
Pageof 2